m290 (rigg2a) antibody against mouse cd103  (Bio X Cell)

Journal: Cell Death & Disease

Article Title: An anti-CD103 antibody-drug conjugate prolongs the survival of pancreatic islet allografts in mice

doi: 10.1038/s41419-019-1980-8

Figure Lengend Snippet: a Splenic lymphocytes from C57BL/6 mice were treated with M290-MC-MMAF at the indicated concentrations for 48 h. The cells were subjected to multicolor FACS analyses using mAbs specific for CD3, CD4, and CD8. Data shown are the mean ± SD, n = 4 independent experiments. b Splenic lymphocytes from C57BL/6 mice were cultured with M290-MC-MMAF at the indicated concentrations for 32 h. FACS analyses were performed to determine the apoptosis/death of the CD4 + and CD8 + compartments using a Dead Cell Apoptosis Kit. Live cells, apoptotic cells, and dead cells are indicated. The data shown are representative of at least three independent experiments. c After stimulation with ConA (4 μg/ml) and treatment with M290-MC-MMAF at the indicated concentrations for 48 h, the proliferation of viable CD4 + or CD8 + compartments was determined. The CFSE low population indicates proliferating cells. Data are the mean ± SD, n = 5 independent experiments. * P < 0.05, ** P < 0.01, one-way ANOVA with Tukey’s multiple comparisons test

Article Snippet: The M290 (rIgG2a) antibody against mouse CD103 was purchased from BioXCell (West Lebanon, NH, USA).

Techniques: Cell Culture

Journal: Cell Death & Disease

Article Title: An anti-CD103 antibody-drug conjugate prolongs the survival of pancreatic islet allografts in mice

doi: 10.1038/s41419-019-1980-8

Figure Lengend Snippet: Histopathological examination of murine tissues treated with M290-MC-MMAF (3 mg/kg) 10 days after the mice received three i.p. injections on days 1, 3, and 5. The photomicrographs do not reveal any evidence of toxicity from the M290-MC-MMAF and show a normal architecture similar to that of the PBS group and M290 group ( n = 6 per group, Scale bars = 50 μm)

Article Snippet: The M290 (rIgG2a) antibody against mouse CD103 was purchased from BioXCell (West Lebanon, NH, USA).

Techniques:

Journal: Cell Death & Disease

Article Title: An anti-CD103 antibody-drug conjugate prolongs the survival of pancreatic islet allografts in mice

doi: 10.1038/s41419-019-1980-8

Figure Lengend Snippet: Diabetic C57BL/6 recipients were transplanted with BALB/c islets and treated with three doses of M290-MC-MMAF (3 mg/kg i.p. injected) or the indicated controls on days 1, 3, and 5 post transplantation. a Blood glucose was monitored every other day post transplantation. The dashed line at 200 mg/dl is considered the threshold for allograft rejection. b Kaplan−Meier plots for graft survival. Graft survival was compared using the log-rank test (*** P = 0.0001 vs. untreated). c Two M290-MC-MMAF-treated recipients developed hyperglycemia after removal of the graft on days 55 and 60 post transplantation

Article Snippet: The M290 (rIgG2a) antibody against mouse CD103 was purchased from BioXCell (West Lebanon, NH, USA).

Techniques: Injection, Transplantation Assay

Journal: Cell Death & Disease

Article Title: An anti-CD103 antibody-drug conjugate prolongs the survival of pancreatic islet allografts in mice

doi: 10.1038/s41419-019-1980-8

Figure Lengend Snippet: a CD103 expression in graft-infiltrating lymphocytes and b splenic and MLN CD8+ T cells were determined by FACS analyses at day 15 post transplantation. c The absolute number of CD8 + T cells in peripheral blood was calculated using TruCount beads. Data are presented as the mean ± SD ( n = 7 per group). The shown percentages are representative data. MLN mesenteric lymph nodes. *** P < 0.001, unpaired t test

Article Snippet: The M290 (rIgG2a) antibody against mouse CD103 was purchased from BioXCell (West Lebanon, NH, USA).

Techniques: Expressing, Transplantation Assay

Journal: Cell Death & Disease

Article Title: An anti-CD103 antibody-drug conjugate prolongs the survival of pancreatic islet allografts in mice

doi: 10.1038/s41419-019-1980-8

Figure Lengend Snippet: a Proportions of splenic FoxP3 + CD4 + CD25 + Tregs were determined by FACS analyses at day 15 post transplantation in mock-treated control mice and at day 60 post-transplantation in long-surviving recipient mice. b Absolute number of CD4 + CD25 + cells in ( a ). CD103 expression in the splenic and MLN CD4 + CD25 + Tregs ( c ) and CD11c + ( d ) cells were determined by FACS analyses at day 60 post transplantation in long-surviving recipient mice ( n = 7 per group). The data shown are representative data. MLN mesenteric lymph nodes. *** P < 0.001, unpaired t test

Article Snippet: The M290 (rIgG2a) antibody against mouse CD103 was purchased from BioXCell (West Lebanon, NH, USA).

Techniques: Transplantation Assay, Control, Expressing

Journal: Cell Death & Disease

Article Title: An anti-CD103 antibody-drug conjugate prolongs the survival of pancreatic islet allografts in mice

doi: 10.1038/s41419-019-1980-8

Figure Lengend Snippet: CD8 + T cells from CD103-depleted C57BL/6 mice (treated with M290-MC-MMAF) ( a ) or WT ( b , c ) were adoptively transferred into long-surviving recipients (>60 days). Donors were intraperitoneally immunized with 1× 10 7 BALB/c splenocytes 4 days before cell isolation. Each line represents blood glucose levels from a single recipient mouse. CD8 + cells for these experiments were enriched by immunomagnetic beads. d An anti-CD25 mAb (PC-61; 500 μg) was i.p. injected into the long-surviving recipient mice (>60 days) to deplete CD25 + CD4 + Tregs. Recipients were treated with rat IgG or PBS as a control. The Kaplan−Meier curve was plotted for graft survival. Graft survival was compared using the log-rank test (** P < 0.01 vs. PBS control)

Article Snippet: The M290 (rIgG2a) antibody against mouse CD103 was purchased from BioXCell (West Lebanon, NH, USA).

Techniques: Cell Isolation, Injection, Control